Array BioPharma and Genentech Expand Strategic Oncology Collaboration

Oct 13, 2005, 01:00 ET from Array BioPharma

    BOULDER, Colo., Oct. 13 /PRNewswire-FirstCall/ -- Array BioPharma
 (Nasdaq:   ARRY) today announced the second extension and expansion of its
 collaboration with Genentech, Inc. (NYSE:   DNA) for the discovery of targeted
 small molecule drugs for the treatment of cancer.
     Under the terms of this expanded agreement, Genentech may provide
 approximately $50 million in research funding to access Array's Drug Discovery
 Platform over the next three years.  Array will be entitled to receive
 milestone payments based on the selection and progression of clinical drug
 candidates, as well as royalties on net sales of any products that may result
 from the collaboration.  Genentech will have the sole responsibility for
 clinical development and commercialization of any resulting products.  Other
 terms were not disclosed.
     Genentech and Array entered into a research collaboration in January 2004
 to advance two of Array's proprietary oncology programs into clinical
 development.  In April 2005, the agreement was expanded to include an
 additional protein target in the field of oncology.  Under the terms of the
 amended agreement Array will receive further consideration based on the
 expanded scope and term of the agreement.
     "We believe our collaboration with Genentech further validates Array's
 leadership position in cancer research," said Robert E. Conway, Chief
 Executive Officer, Array BioPharma.  "This collaboration leverages Array's
 proprietary small molecule drug discovery expertise with Genentech's cancer
 expertise, with the goal of creating products to address one of the world's
 largest unmet medical needs and market opportunities."
     About Array BioPharma
     Array BioPharma is a biopharmaceutical company focused on the discovery,
 development and commercialization of orally active drugs to address
 significant unmet medical needs.  Our proprietary drug development pipeline is
 primarily focused on the treatment of cancer and inflammatory disease and
 includes several small molecule drug candidates that are designed to regulate
 targets in therapeutically important biologic pathways.  In addition, leading
 pharmaceutical and biotechnology companies access our drug discovery
 technologies and expertise through collaborations to design, create, optimize
 and evaluate drug candidates across a broad range of therapeutic areas.  For
 more information on Array, please go to
     Array Forward-Looking Statement:
     This press release contains forward-looking statements within the meaning
 of the Private Securities Litigation Reform Act of 1995 that involve
 significant risks and uncertainties, including those discussed in our annual
 report filed on form 10-K for the year ended June 30, 2005, and in other
 reports filed by Array with the Securities and Exchange Commission.  Because
 these statements reflect our current expectations concerning future events,
 our actual results could differ materially from those anticipated in these
 forward-looking statements as a result of many factors.  These factors include,
 but are not limited to, our ability to achieve and maintain profitability, the
 extent to which the pharmaceutical and biotechnology industries are willing to
 in-license drug candidates for their product pipelines and to collaborate with
 and fund third parties for their drug discovery activities, our ability to
 out-license our proprietary candidates on favorable terms, our ability to
 continue to fund and successfully progress internal research efforts and to
 create effective, commercially viable drugs, risks associated with our
 dependence on our collaborators for the clinical development and
 commercialization of our out-licensed drug candidates, the ability of our
 collaborators and of Array to meet drug objectives, including clinical trials,
 tied to milestones and royalties, and our ability to attract and retain
 experienced scientists and management.  We are providing this information as
 of October 13, 2005.  We undertake no duty to update any forward-looking
 statements to reflect the occurrence of events or circumstances after the date
 of such statements or of anticipated or unanticipated events that alter any
 assumptions underlying such statements.

SOURCE Array BioPharma